Olaparib Patent Expiration

Olaparib is Used for treating various types of cancers, including breast, ovarian, pancreatic, and metastatic prostate cancer, in patients with specific gene mutations undergoing specific chemotherapy regimens. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Lynparza on Dec 19, 2014.


Olaparib Patents

Given below is the list of patents protecting Olaparib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Lynparza US11970530 Methods of treating homologous recombination deficient cancer Oct 25, 2041 Astrazeneca
Lynparza US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug 04, 2031 Astrazeneca
Lynparza US8475842 Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Dec 31, 2029 Astrazeneca
Lynparza US11633396 Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one Oct 07, 2029 Astrazeneca
Lynparza US11975001 Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Oct 07, 2029 Astrazeneca
Lynparza US12048695 Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Oct 07, 2029 Astrazeneca
Lynparza US8247416 Phthalazinone derivative Sep 24, 2028 Astrazeneca
Lynparza US7449464 Phthalazinone derivatives Sep 08, 2027 Astrazeneca
Lynparza US8071579 DNA damage repair inhibitors for the treatment of cancer Aug 12, 2027 Astrazeneca
Lynparza US8143241 DNA damage repair inhibitors for treatment of cancer Aug 12, 2027 Astrazeneca
Lynparza US7449464 Phthalazinone derivatives Oct 11, 2024

(Expired)

Astrazeneca
Lynparza US7981889 Phthalazinone derivatives Oct 11, 2024

(Expired)

Astrazeneca
Lynparza US8912187 Phthalazinone derivatives Mar 12, 2024

(Expired)

Astrazeneca
Lynparza US9169235 Phthalazinone derivatives Mar 12, 2024

(Expired)

Astrazeneca
Lynparza US9566276 Phthalazinone derivatives Mar 12, 2024

(Expired)

Astrazeneca
Lynparza US7151102 Phthalazinone derivatives Apr 29, 2022

(Expired)

Astrazeneca



Olaparib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Olaparib News

AstraZeneca and Merck introduce a new patent in their efforts to protect Lynparza from generic competition

21 Nov, 2024

See More